Jump to the top of the page

William Blair Thinking

  • As GP-Led Secondaries Grow, So Has Related Use of Reps and Warranties Insurance

    With GP-led secondaries setting records in 2024—and trendlines looking promising for 2025—secondary investors have increasingly turned to M&A-style insurance policies to facilitate their transactions.

    Read more
  • Exploring Energy Economics With Dr. Carey W. King

    Dr. Carey W. King from the University of Texas at Austin delves into the intricate relationship between energy systems, the economy, and the environment, exploring his innovative HARMONEY Model and discussing the critical role of energy in shaping macroeconomic policies and future sustainability.

    Listen to the podcast
  • Beyond Dogs and Cats: Exploring Growth in Other Backyard Animals and Wildlife

    Backyard animals like chickens and horses, as well as small companion animals, are becoming increasingly popular among pet parents, retailers, and companies supplying products to the pet and animal industry.

    Read more

Our Mission, Vision, and Values

At William Blair, we're committed to our colleagues, our clients, and our communities. Serving our clients starts with the capabilities and collaboration of our team—making our employees our most important asset. When we create an environment where employees perform their best, our delivery for clients will be the best it can be.

Learn more about our mission, vision, and values

Global Community Partners

We are proud of our signature Global Community Partners program, through which employees nominate organizations to receive catalytic financial support and significant volunteerism opportunities every two years.

More about our community partners

Our Latest News

  • William Blair Initiates Coverage of Seven Companies in the Obesity Treatment Space

    William Blair initiated research coverage of Altimmune, Inc. (ALT $5.91), BioAge Labs, Inc. (BIOA $4.18), Corbus Pharmaceuticals Holdings, Inc. (CRBP $7.50), Skye Bioscience, Inc. (SKYE $2.89), Structure Therapeutics, Inc. (GPCR $21.09), Terns Pharmaceuticals, Inc. (TERN $3.71), and Zealand Pharma A/S (ZEAL-CSE DKK 719.00).

    Read more
  • Mapal OS Has Completed a Dividend Recapitalization

    William Blair acted as exclusive financial advisor to Mapal OS, a portfolio company of PSG Equity, in connection with its dividend recapitalization.

    Read more
  • Naviant Has Received a Strategic Investment from DNS Capital

    William Blair acted as the exclusive financial advisor to Naviant in connection with its strategic investment from DNS Capital.

    Read more

Join Our Team

Finding, attracting, and developing talented people is the foundation of our success. Learn about the promising career opportunities currently available at William Blair.

Search our job openings
Women sitting outside with a laptop

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures